Controlled Substance Analogs and Novel Psychedelics: Where Does the Law Draw the Line?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who has encountered compounds like 1cP-LSD, 4-AcO-DMT, or other “research chemicals” marketed online, and wants to understand where these substances actually stand under federal law — and why the answer is not as simple as “legal because it’s not on the list.”

The short answer

A substance does not need to appear on the DEA’s controlled substances list to be prosecutable as a federal crime. The Federal Analogue Act, enacted in 1986, extends the reach of the Controlled Substances Act to cover any compound that is substantially similar in chemical structure or pharmacological effect to a Schedule I or II substance — if it is intended for human consumption. Compounds marketed as “research chemicals” or labeled “not for human consumption” do not escape this reach automatically. Courts have repeatedly found that those labels are evidence, not defenses.

What the Federal Analogue Act is

The Federal Analogue Act is codified at 21 U.S.C. § 813, added to the Controlled Substances Act by the Controlled Substances Analogue Enforcement Act of 1986. It provides that a controlled substance analogue shall, to the extent intended for human consumption, be treated for the purposes of any federal law as a controlled substance in Schedule I.

The statute defines a controlled substance analogue as a substance that meets at least one of three conditions under 21 U.S.C. § 802(32)(A):

Its chemical structure is substantially similar to the chemical structure of a controlled substance in Schedule I or II
It has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than that of a Schedule I or II substance
It is represented or intended by a particular person to have a stimulant, depressant, or hallucinogenic effect substantially similar to that of a Schedule I or II substance

The third condition is particularly broad. Under 21 U.S.C. § 813, a substance can qualify as a controlled substance analogue based solely on the third condition — that is, a seller or user represents or intends the substance to produce effects similar to a controlled drug — without any chemical similarity at all. Federal prosecutors have successfully used this provision.

The “not for human consumption” problem

The Analogue Act only applies to substances intended for human consumption. This created the research chemical market: vendors sell novel psychoactive compounds with labels reading “not for human consumption,” “for research purposes only,” or “not for sale to minors,” explicitly because the human consumption requirement is the legal trigger.

Federal courts have repeatedly rejected this label as a defense where the surrounding circumstances demonstrate the substance was actually intended for consumption. The DEA’s testimony before Congress has characterized these disclaimers as a “sham” in cases where the totality of evidence — pricing, packaging, marketing context, the absence of any legitimate research use — shows the substance was sold to be ingested. Convictions have followed even when product labeling contained explicit warnings against consumption.

Critically, 21 U.S.C. § 813 states directly that “evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption.” The label alone does not resolve the question. Courts consider multiple factors including the marketing context, the difference between the sale price and the legitimate research price for the same compound, known patterns of use, and whether the seller knew or should have known the substance would be consumed.

What “substantially similar” means — and why it is contested

The phrase “substantially similar” is not defined in the statute. This has produced litigation in courts across the country, with prosecution and defense chemists regularly offering competing testimony about whether a particular molecular modification renders a compound substantially similar to or distinct from a scheduled substance.

The lack of a precise definition led a Colorado district court in United States v. Forbes (1992) to find the Analogue Act unconstitutionally vague as applied to the compound alpha-ethyltryptamine. The Eighth Circuit upheld the Act’s constitutionality in United States v. Washam (2002), finding that a person of ordinary intelligence has sufficient notice that a compound metabolized into a Schedule I substance and with near-identical structure would be treated as an analogue. Justice Neil Gorsuch, before his appointment to the Supreme Court, raised constitutional vagueness concerns about the statute.

The practical result is genuine legal uncertainty. A compound one atom away from a scheduled substance may or may not be found substantially similar, depending on which circuit’s precedents apply, which expert chemists testify, and which theory of chemical similarity the court accepts. No defendant should treat this uncertainty as safety. The Eighth Circuit’s reasoning in Washam — that ordinary people know that selling something to get people high is risky — has been adopted in other circuits.

Where specific compounds stand

1cP-LSD is not on the DEA’s Schedule I list as an explicitly scheduled substance. It is a prodrug of LSD — meaning the body metabolizes it into LSD. Under the Analogue Act, it could be treated as a controlled substance in any federal prosecution where it is found to be substantially similar to LSD and intended for human consumption. Its status is not “legal.” It is unscheduled, which is different.

4-AcO-DMT (psilacetin) is not explicitly scheduled under federal law. It is chemically an analogue of psilocin, a Schedule I substance. Under the Analogue Act, its manufacture, distribution, or possession for human consumption could be prosecuted as if it were psilocin. Multiple states, including Alabama, have explicitly scheduled it as a controlled substance under state law, removing the analogue ambiguity in those jurisdictions.

1P-LSD is similarly unscheduled federally and in Canada. It is widely understood to be an LSD prodrug. The same Analogue Act analysis applies.

The pattern across these compounds is consistent: they are sold as unscheduled because they are not on the DEA’s explicit list. They are not legal in any meaningful sense if intended for human consumption, and in many jurisdictions they are explicitly illegal under state law regardless of the federal analogue analysis.

Temporary scheduling as a parallel mechanism

The DEA also has authority under 21 U.S.C. § 811(h) to temporarily place a substance in Schedule I without following the full rulemaking process if the Attorney General finds that scheduling is necessary to avoid an imminent hazard to the public safety. A temporary scheduling order lasts for two years and can be extended by one additional year. The DEA has used this authority frequently to address synthetic cannabinoids, synthetic cathinones, and novel opioid analogues that emerged faster than standard rulemaking could capture them.

The existence of temporary scheduling means that a compound’s current unscheduled status provides no guarantee of future unscheduled status. Compounds that attract law enforcement attention or generate adverse event reports can move to Schedule I within months.

Why the research chemical market exists — and what it misrepresents

Novel psychoactive compounds are sold as research chemicals partly because they have, at various points, filled gaps that the explicit scheduling list leaves open. The compounds are typically sold online, often from international vendors, with “not for human consumption” labels intended to exploit the human consumption requirement of the Analogue Act.

The characterization as “research chemicals” misrepresents the legal situation in two ways. First, actual scientific research on Schedule I substances requires DEA registration, FDA authorization for clinical trials, institutional oversight, and strict compliance protocols — none of which these vendors or their customers have. Second, buying a compound labeled “research chemical” does not insulate a purchaser from prosecution if the government can establish intent for human consumption. The label is a commercial strategy with no legal force against a prosecutor who can demonstrate actual intent for human consumption.

Common mistakes and misconceptions

“It’s not on the DEA list, so it’s legal.” Unlisted does not mean unregulated. The Analogue Act covers unlisted compounds that meet the substantial similarity test. Several states schedule compounds independently of federal law, creating additional liability.

“The label says not for human consumption, so I’m protected.” Courts have rejected this defense where surrounding circumstances demonstrate intent for consumption. The statute explicitly states this label alone is not sufficient to establish the substance was not intended for human consumption.

“It’s been sold openly for years without prosecutions, so it must be okay.” Prosecution history is not legal status. Low prosecution rates for specific compounds reflect enforcement priorities, not legal authorization. The DEA has conducted large-scale operations targeting research chemical vendors — including a 2004 operation resulting in 10 arrests and a 2012 operation resulting in 90 arrests and seizure of 36 million dollars in cash.

“This is different from scheduled drugs because it’s synthesized for research.” If the compound is substantially similar to a scheduled substance and intended for human consumption, the fact of synthesis for purported research purposes does not change the Analogue Act analysis.

When public information may be enough

If your question is how the Analogue Act works in general and why research chemicals are not simply legal, this article covers it. For the broader federal scheduling framework, see What is the Controlled Substances Act and how does it affect psychedelics? and What is a DEA Schedule I substance and what does that mean practically?.

When you should speak with a lawyer

You should speak with a lawyer if:

You have been charged with or are under investigation for possession, distribution, or manufacture of a novel psychoactive compound
You are operating a business that sells compounds that could fall under the Analogue Act’s reach
You are a researcher working with compounds that may be analogues of scheduled substances and want to understand your compliance obligations
You have been contacted by law enforcement in connection with any novel psychoactive compound, whether or not it is explicitly scheduled

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.